| Dutch tariff for the five-level version of EQ-5D MM Versteegh, KM Vermeulen, SMAA Evers, GA De Wit, R Prenger, ... Value in health 19 (4), 343-352, 2016 | 671 | 2016 |
| Time trade-off: one methodology, different methods AE Attema, Y Edelaar-Peeters, MM Versteegh, EA Stolk The European Journal of Health Economics 14, 53-64, 2013 | 137 | 2013 |
| Patient and general public preferences for health states: a call to reconsider current guidelines MM Versteegh, WBF Brouwer Social Science & Medicine 165, 66-74, 2016 | 124 | 2016 |
| Introducing the composite time trade-off: a test of feasibility and face validity BMF Janssen, M Oppe, MM Versteegh, EA Stolk The European Journal of Health Economics 14, 5-13, 2013 | 120 | 2013 |
| Condition-specific preference-based measures: benefit or burden? MM Versteegh, A Leunis, CA Uyl-de Groot, EA Stolk Value in Health 15 (3), 504-513, 2012 | 107 | 2012 |
| When is it too expensive? Cost-effectiveness thresholds and health care decision-making W Brouwer, P van Baal, J van Exel, M Versteegh The European Journal of Health Economics 20, 175-180, 2019 | 87 | 2019 |
| From good to better: new Dutch guidelines for economic evaluations in healthcare M Versteegh, S Knies, W Brouwer Pharmacoeconomics 34, 1071-1074, 2016 | 81 | 2016 |
| Mapping onto Eq-5 D for patients in poor health MM Versteegh, D Rowen, JE Brazier, EA Stolk Health and Quality of life Outcomes 8, 1-13, 2010 | 72 | 2010 |
| Mapping Qlq-C30, Haq, and Msis-29 on Eq-5d MM Versteegh, A Leunis, JJ Luime, M Boggild, CA Uyl-de Groot, EA Stolk Medical Decision Making 32 (4), 554-568, 2012 | 60 | 2012 |
| Severity-adjusted probability of being cost effective MM Versteegh, IC Ramos, NC Buyukkaramikli, A Ansaripour, ... Pharmacoeconomics 37, 1155-1163, 2019 | 58 | 2019 |
| Lead time TTO: leading to better health state valuations? AE Attema, MM Versteegh, M Oppe, WBF Brouwer, EA Stolk Health economics 22 (4), 376-392, 2013 | 48 | 2013 |
| Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma S de Groot, WK Redekop, MM Versteegh, S Sleijfer, E Oosterwijk, ... Quality of Life Research 27, 115-124, 2018 | 45 | 2018 |
| A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending P van Baal, M Perry‐Duxbury, P Bakx, M Versteegh, E Van Doorslaer, ... Health economics 28 (1), 87-100, 2019 | 43 | 2019 |
| Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the … IC Ramos, MM Versteegh, RA de Boer, JMA Koenders, GCM Linssen, ... Value in Health 20 (10), 1260-1269, 2017 | 38 | 2017 |
| Are health state valuations from the general public biased? A test of health state reference dependency using self‐assessed health and an efficient discrete choice experiment MF Jonker, AE Attema, B Donkers, EA Stolk, MM Versteegh Health economics 26 (12), 1534-1547, 2017 | 33 | 2017 |
| An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences R Crott, M Versteegh, C Uyl-de-Groot Quality of Life Research 22, 1045-1054, 2013 | 33 | 2013 |
| Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-AD) C Koedoot, M Versteegh, JS Yaruss Journal of Fluency Disorders 36 (3), 222-230, 2011 | 30 | 2011 |
| Time to tweak the TTO: results from a comparison of alternative specifications of the TTO MM Versteegh, AE Attema, M Oppe, NJ Devlin, EA Stolk The European Journal of Health Economics 14, 43-51, 2013 | 28 | 2013 |
| Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options MF Jonker, B Donkers, LMA Goossens, RJ Hoefman, LJ Jabbarian, ... Medical Decision Making 40 (2), 198-211, 2020 | 24 | 2020 |
| Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma DT Arnold, D Rowen, MM Versteegh, A Morley, CE Hooper, NA Maskell Health and quality of life outcomes 13, 1-10, 2015 | 21 | 2015 |
